ClinicalTrials.gg
RecruitingNCT06554353COEDUpdated Jun 3, 2026

Cardiopulmonary Exercise Testing and Oscillometry for the Evaluation of Dyspnea

An observational study in Breathing, Mouth, Lung Function Decreased and Dyspnea, sponsored by University of Rochester. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-03.

Sponsored by University of Rochester · Observational

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
18 Years and older
Sex
All
01

Study summary

This study will determine if airway resistance to airflow and pressure, measured by Oscillometry, is associated with abnormal findings on Cardiopulmonary Exercise Testing in subjects who are experiencing shortness of breath.

02

Conditions studied

  • Breathing, Mouth
  • Lung Function Decreased
  • Dyspnea
  • Shortness of Breath
03

In context

Mouth Breathing

33 studies on the registry are indexed under Mouth Breathing; 4 are open to participants now.

Browse Mouth Breathing studies →

Lead sponsor

University of Rochester is the lead sponsor of 729 studies on the registry; 116 are open to participants now.

Of its 56 completed or terminated interventional studies of FDA-regulated products, 44 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Up to fifty (50) human subjects will be recruited from the following University of Rochester locations: Mary Parkes Center for Asthma, Allergy, and Pulmonary Care, the Pulmonary Clinic at Strong Memorial Hospital, and The Pulmonary Clinic at Highland Hospital.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willingness to perform breathing test
  • Must be able to speak and understand English
  • Referred for Cardiopulmonary Exercise Testing

Exclusion criteria

Exclusion Criteria:

  • Unable to provide consent or perform oscillometry test
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • Subjects with dyspnea referred for Cardiopulmonary Exercise Testing

    Subjects with unexplained dyspnea referred for Cardiopulmonary Exercise Testing.

    Device: Oscillometer

Interventions

  • DeviceOscillometer

    The tremoFlo C-100 Airwave Oscillometry System is intended to measure respiratory system impedance using the Forced Oscillation Technique (FOT).

    Also known as: THORASYS tremoFlo C-100 Airwave Oscillometry System

06

What researchers measure

Primary outcomes

  1. Mean respiratory system resistance and reactance

    The oscillometer will collect an airway impedance measurement which is made up of multiple variables.

    Time frame: Single measurement, approximately day 1

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2024 to primary completion in May 2026, 18 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2024
First posted
Aug 15, 2024
StartActual
Oct 29, 2024
Primary completionActual
May 1, 2026
CompletionEst.
Nov 30, 2026
Last update
Jun 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06554353
Responsible party
Patrick Donohue (Assistant Professor, University of Rochester) — Principal investigator
First posted
Aug 15, 2024
Start date
Oct 29, 2024
Primary completion
May 1, 2026
Completion
Nov 30, 2026 (estimated)
Last update
Jun 3, 2026

Study contacts

PATRICK DONOHUE, MD
Contact
patrick_donohue@urmc.rochester.edu
716-226-8429

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion